8. GRAIL Inc. (NASDAQ:GRAL)
Number of Hedge Fund Investors: 28
Market Capitalization as of February 24: $1.54 billion
GRAIL Inc. (NASDAQ:GRAL) is a biotechnology company focusing on developing the next generation of cancer diagnostic tools that will help doctors identify dangers early on and maybe prevent lethal diseases from causing damage, making it a promising treatment. It was originally developed within Illumina, spun off in 2016, reacquired in 2021, and eventually divested again in 2024 following a dispute with European regulators. Still, shares are up, and Bezos Expeditions has been on board, with the business maintaining a large stake in the company and being included in Jeff Bezos Stock Portfolio.
GRAIL Inc. (NASDAQ:GRAL) reported a significant growth in Galleri revenue in the United States, which climbed by 45% YoY to over 137,000 Galleri tests sold. Fourth-quarter 2024 revenue surged by 26% to $38.3 million, contributing to full-year revenue of $125.6 million, a 35% increase over 2023. The company improved cost efficiency by introducing a new Galleri test version, cutting sequencing costs, automating procedures, and expanding lab capacity. Strategic collaborations with Quest Diagnostics made test ordering simpler, while TRICARE approval increased coverage for some patients. The net loss improved by 48% in Q4, and cash burn is anticipated to drop by more than 40% by 2025.
Its stock has shot up by more than 127% in 2025. GRAIL Inc. (NASDAQ:GRAL) declared sales of $124-126 million for 2024, above estimates, and reported 137,000 tests sold, up from 94,000 in 2023. Larry Ellison, Oracle’s Chief Technology Officer and former CEO, remarks on the use of blood tests for cancer vaccinations, as well as the partnership with Quest Diagnostics, which provides access to over 500,000 providers, has strengthened the trust of investors.
